新加坡微小核糖核酸(miRNA)技术公司MIRXES-B(2629.HK)今日盘中一度涨8.1%至47.8港元，股价创上市新高，市值约132亿港元。该股于今年5月23日登陆 港交所，上市迄今不到3个月，现价较发行价23.3港元已累涨105%。 MIRXES-B公告，公司间接全资附属公司MiRXESPTE. LTD.近期已与PT DIASTIKA BIOTEKINDO(一间于印尼证券交易所上市的公司)订立一份谅解备忘 录，据此，双方同意在印尼进行用于高发病率及高死亡率癌症早期检测及诊断的分子诊断检测及相关仪器的注册及商业化方面进行合作。谅解备忘录期限自 签署日期起计为期12个月。董事会相信订立谅解备忘录乃集团推动全球化策略并将业务扩张至高潜力新兴市场的关键举措。(格隆汇) ...

Group 1 - The company MiRXES-B (02629) has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows the company to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics testing devices for high-incidence cancers such as gastric and lung cancer [1] Group 2 - The partnership enables the company to benefit from local policies in Indonesia, such as tax incentives for localization rates of 40% [1] - The collaboration aims to achieve regulatory flexibility under the ASEAN-centered medical device framework [1] - Indonesia is positioned as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [1]